3
Participants
Start Date
August 20, 2024
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2026
Empasiprubart IV
Intravenous infusion with Empasiprubart IV
Placebo IV
Intravenous infusion with Placebo IV
Timofei Mosneaga Republican Clinical Hospital, Chisinau
National and Kapodistrian University of Athens (NKUA) - University General Hospital Attikon, Athens
Nova Reuma Domyslawska i Rusilowicz- Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty, Bialystok
Andreas Syggros Hospital of Skin and Venereal Diseases - University Dermatology and Venereology, Athens
University of Florida Health (UF) - Endocrinology - Medical Specialties - Medical Plaza, Gainesville
Omega Research Debary, LLC, DeBary
Homestead Associates in Research, Inc., Homestead
Life Clinical Trials, Margate
Advance Medical Research Center, Miami
D and H Tamarac Research, LLC Center, Tamarac
Integral Rheumatology and Immunology Specialists (IRIS), Plantation
Hospital Quironsalud Infanta Luisa, Seville
Wright State Physicians Health Center, Dayton
Hospital Universitario Rio Hortega, Valladolid
Azienda Ospedaliera Universitaria Pisana, Pisa
General Hospital of Thessaloniki Papageorgiou, Thessaloniki
Profound Research LLC, Oceanside
V.Tsitlanadze Scientific Practical Reumatology Center, Tbilisi
The First University Clinic of Tbilisi State Medical University, Tbilisi
Institute of Clinical Cardiology, Ltd, Tbilisi
Jerarsi Clinic, Tbilisi
Mtskheta street Clinic, Tbilisi
The First Medical Center, Tbilisi
Fondazione Policlinico Universitario Campus Bio-Medico, Rome
Institute of Cardiology, Chisinau
Prywatna Praktyka Lekarska Prof. UM dr Hab. Med. Pawel Hrycaj, Poznan
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw
Parc de Salut Mar - Hospital del Mar, Barcelona
Lead Sponsor
argenx
INDUSTRY